Nilagel500 mg

Nilagel is a herbal (nutraceutical) supplement derived from the seeds of the Nigella sativa plant, commonly known as black seed or black cumin. It is used in traditional and complementary medicine for a variety of purported health benefits. Overall clinical evidence for most uses remains limited and preliminary compared with conventional pharmacotherapy, so it should be regarded as a supportive or adjunct measure rather than a replacement for prescribed treatment.

• General wellness and immune support (traditional use; limited controlled trial evidence).
• Adjunct support for allergic conditions such as allergic rhinitis (some small trials suggest symptom improvement when used alongside standard allergy treatment).
• Adjunct support for asthma and chronic respiratory symptoms when used together with, not in place of, physician-prescribed inhalers/medication.
• Adjunct support for blood glucose management in type 2 diabetes, used together with, not instead of, prescribed antidiabetic therapy (preliminary evidence of modest glucose-lowering effect).
• Adjunct support for mild blood pressure and lipid (cholesterol) management alongside standard therapy (preliminary evidence of modest effects on blood pressure and lipid profile).
• Adjunct use in H. pylori eradication regimens together with standard combination therapy (not as monotherapy).
• General digestive and respiratory wellness (long traditional use; evidence base is largely observational/preliminary).

These uses are supported mainly by small clinical trials, traditional use, and preliminary evidence; Nilagel is not a substitute for prescribed medical therapy, and any use for a diagnosed medical condition should be discussed with a physician.

Each formulation of Nigella Sativa [Black Seed Oil] is prepared as a soft-gelatin capsule or liquid oil containing cold-pressed oil obtained from the seeds of Nigella sativa. The oil naturally contains a range of bioactive constituents, the most studied of which is thymoquinone, along with other volatile oils, fatty acids (including linoleic and oleic acid), and minor phenolic compounds. No synthetic active pharmaceutical ingredient is added; potency can vary between batches depending on extraction method and seed source.

Nilagel is a herbal supplement made from the seed oil of Nigella sativa, an annual flowering plant native to South and Southwest Asia, also known as black seed, black cumin, or kalonji. The seeds and their oil have been used for thousands of years in traditional Middle Eastern, South Asian, and Unani/Ayurvedic medicine systems.

In modern use, Nilagel is marketed as a dietary/herbal supplement rather than a conventional prescription drug. It is not FDA-approved as a drug for any disease indication; its regulatory status in most markets, including Bangladesh, is that of a herbal/nutraceutical product. Users should have realistic expectations: available clinical evidence is generally from small or short-duration studies, and quality/standardization of commercial products can vary.

Herbal supplement / Nutraceutical (Complementary and Alternative Medicine agent) — Nilagel

The principal bioactive constituent of Nigella Sativa [Black Seed Oil] is thymoquinone, a naturally occurring compound believed to be responsible for most of its reported pharmacological effects. Proposed mechanisms, based largely on laboratory and small clinical studies, include:

• Antioxidant activity — scavenging of free radicals and reduction of oxidative stress markers.
• Anti-inflammatory activity — modulation of inflammatory mediators (e.g. cytokines, prostaglandins).
• Immunomodulatory activity — effects on immune cell function reported in preliminary studies.
• Mild hypoglycemic effect — modest reduction in fasting blood glucose and HbA1c reported in some trials in people with type 2 diabetes.
• Mild antihypertensive and lipid-modulating effect — small reductions in blood pressure, total cholesterol, LDL, and triglycerides reported in some trials.
• Mild antiplatelet effect — some evidence of reduced platelet aggregation/blood clotting, relevant to bleeding risk (see Interactions and Precautions).

These effects are generally modest in magnitude and have not been established with the same rigor as conventional pharmacological agents.

Nilagel capsules should be swallowed whole with water, preferably with meals to reduce the chance of stomach upset. If using the liquid oil form, it may be taken directly by mouth or mixed with food/water as directed on the product label. Do not exceed the labeled or physician-recommended dose.

Nilagel has clinically relevant interactions with several drug classes, primarily because of its mild blood-glucose-lowering, blood-pressure-lowering, and anti-clotting effects:

• Antidiabetic drugs (e.g. insulin, sulfonylureas, metformin): additive blood-glucose-lowering effect is theoretically possible; concurrent use may increase risk of hypoglycemia. Monitor blood glucose closely.
• Antihypertensive drugs: additive blood-pressure-lowering effect is theoretically possible; concurrent use may increase risk of hypotension. Monitor blood pressure.
• Anticoagulants and antiplatelet agents (e.g. warfarin, aspirin, clopidogrel): may potentiate the antiplatelet/anticoagulant effect, increasing the risk of bruising or bleeding. Use with caution and monitor for bleeding signs.
• Sedatives/CNS depressants: theoretical additive sedative effect; use with caution.
• Immunosuppressant drugs: immune-modulating activity of Nilagel could theoretically interfere with immunosuppressive therapy; caution advised in transplant/autoimmune patients on such therapy.

Patients should inform their physician or pharmacist of all prescription medicines, herbal products, and supplements they take before starting Nilagel.

Nilagel is generally well tolerated when used short-term at recommended doses. Reported side effects include:

• Gastrointestinal upset — nausea, stomach discomfort, bloating, or constipation.
• Allergic skin reactions — rash, itching, or contact dermatitis, particularly with topical use.
• Mild hypotension or hypoglycemia symptoms (dizziness, lightheadedness, sweating) — more likely if combined with blood-pressure or glucose-lowering drugs (see Interaction).
• Increased bruising or bleeding tendency in susceptible individuals (see Precautions and Warnings).

Data on safety of long-term or high-dose use of Nilagel are limited.

Pregnancy: Safety data for Nilagel in pregnancy are insufficient. Amounts beyond typical dietary/culinary use are generally not recommended during pregnancy, as some data suggest a possible effect on uterine muscle activity. Nilagel should be used in pregnancy only if clearly needed, and only under medical guidance, after the potential benefit has been weighed against potential risk to the fetus by a physician.

Lactation: There is insufficient reliable evidence on the safety of Nilagel during breastfeeding. It should be used during lactation only on the advice of a physician.

Use Nilagel with caution in the following situations:

• Bleeding disorders / anticoagulant or antiplatelet therapy: Nilagel may have mild antiplatelet/anticoagulant-potentiating effects; caution is advised in patients with bleeding disorders or those on blood-thinning medication (see Interaction).
• Surgery: because of possible effects on blood clotting, it is advisable to stop Nilagel at least two weeks before any planned surgical procedure.
• Diabetes and hypertension: Nilagel may have mild hypoglycemic and antihypertensive effects; monitor blood glucose and blood pressure closely if used together with diabetes or blood pressure medication, as additive effects are theoretically possible.
• Hypersensitivity: discontinue immediately if signs of an allergic reaction occur (see Contraindications).
• Product quality: since Nilagel is a herbal product, potency and purity can vary between manufacturers; use a reputable, quality-assured product.

There is no well-established human overdose syndrome or specific antidote for Nilagel. Taking substantially more than the recommended dose may increase the likelihood of gastrointestinal upset, hypotension, hypoglycemia, or increased bleeding tendency. If overdose is suspected, or if severe symptoms (fainting, severe dizziness, unusual bleeding) occur, seek immediate medical attention or contact a poison control center/emergency services rather than attempting home treatment.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Renal impairment: data on the use of Nilagel in patients with renal impairment are insufficient; use with caution and under medical supervision.

Hepatic impairment: data on the use of Nilagel in patients with hepatic impairment are insufficient; use with caution and under medical supervision.

Elderly: no specific dose adjustment is established, but elderly patients are more likely to be on interacting medications (antidiabetics, antihypertensives, anticoagulants); monitor closely (see Interaction).

Pediatric population: see Pediatric Use.

Nilagel is typically used for defined trial periods rather than indefinitely, most commonly for about 4 to 12 weeks in clinical studies for a given purpose (e.g. glucose or lipid support). Long-term safety data beyond this duration are limited. Response and continued need for Nilagel should be reassessed with a physician periodically, particularly if it is being used alongside prescribed medication for a diagnosed condition.

Herbal supplement; Complementary and Alternative Medicine (CAM) agent — Nigella Sativa [Black Seed Oil]

The reported mode of action of Nigella Sativa [Black Seed Oil] centers on its principal constituent, thymoquinone, which exhibits antioxidant and anti-inflammatory activity in laboratory and clinical studies. Proposed effects include scavenging of reactive oxygen species, modulation of inflammatory cytokine pathways, and mild modulation of glucose, lipid, and blood pressure regulation. See Pharmacology for further detail.

Formal pediatric safety and efficacy data for Nilagel are limited, so its use in children should always be under medical supervision. Common market convention in Bangladesh is:

• Children 5–15 years: 1 capsule once daily, or as directed by a physician.
• Children under 5 years: use is not recommended; safety and efficacy are not established in this age group.

Parents/caregivers should consult a pediatrician before giving Nilagel to a child, particularly if the child has an underlying medical condition or takes other medication.